Paolo Strati, M.D.

Peer-Reviewed Articles

1. Ashley, PA, Strati, P, Taherian, M, Mulanovich, VE, Ariza Heredia, E. Whipple's disease in a patient with follicular lymphoma. Diagnostic Microbiology and Infectious Disease 112(2), 2025. e-Pub 2025. PMID: 40043335.
2. Strati, P, Agajanian, R, Lossos, IS, Coleman, M, Kridel, R, Wood, A, Lesley, R, Wun, CC, Stephens, DM. Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology 206(3):887-898, 2025. e-Pub 2025. PMID: 39667721.
3. Ghobadi, A, Bachanova, V, Patel, K, Park, JH, Flinn, IW, Riedell, PA, Bachier, CR, Diefenbach, CS, Wong, C, Bickers, C, Wong, L, Patel, D, Goodridge, J, Denholt, M, Valamehr, B, Elstrom, RL, Strati, P. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma. The Lancet 405(10473):127-136, 2025. e-Pub 2025. PMID: 39798981.
4. Manzar, G, Pinnix, CC, Dudzinski, SO, Marqueen, KE, Cha, E, Nasr, L, Yoder, A, Rooney, MK, Strati, P, Ahmed, S, Nze, CC, Nair, R, Fayad, LE, Wang, L, Nastoupil, L, Westin, JR, Flowers, CR, Neelapu, SS, Gunther, J, Dabaja, BS, Wu, SY, Fang, PQ. Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 39958356.
5. Wu, SY, Fang, PQ, Fetooh, A, Manzar, G, Corrigan, KL, Schrank, BR, Nasr, L, Chihara, D, Castillo, LM, Nair, R, Steiner, RE, Jain, P, Neelapu, SS, Strati, P, Nastoupil, L, Dabaja, BS, Pinnix, CC, Gunther, J. Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung. Advances in Radiation Oncology 9(12), 2024. e-Pub 2024. PMID: 39524525.
6. Fang, PQ, Noticewala, SS, Wu, SY, Gunther, J, Ludmir, EB, Medeiros, LJ, Strati, P, Nair, R, Nze, CC, Nastoupil, L, Ahmed, S, Castillo, LM, Fayad, LE, Westin, J, Neelapu, SS, Flowers, CR, Huen, A, Iyer, SP, Dabaja, BS, Pinnix, CC. Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type. Advances in Radiation Oncology 9(12), 2024. e-Pub 2024. PMID: 39553398.
7. Strati P, Champion R, Coleman M, Smith SM, Venugopal P, Martin P, Wood A, Miller K, Christian B. Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study. Br J Haematol, 2024. e-Pub 2024. PMID: 39308028.
8. Manzar GS, Wu SY, Dudzinski SO, Cha EE, Yoder AK, Corrigan KL, Nasr LF, Sallard G, Ahmed S, Fayad LE, Chihara D, Nair R, Westin JR, Daher M, Neelapu SS, Nastoupil LJ, Gunther JR, Pinnix CC, Dabaja BS, Strati P, Fang PQ. Characterization of lymphopenia and correlating the risk of cytopenias with dose and BM volume irradiated in aggressive B-cell lymphoma patients bridged with radiation therapy for CAR-T cell therapy. Int J Radiat Oncol Biol Phys, 2024. e-Pub 2024. PMID: 39303997.
9. Pinnix CC, Dabaja BS, Gunther JR, Fang PQ, Wu SY, Nastoupil LJ, Strati P, Nair R, Ahmed S, Steiner R, Westin J, Neelapu S, Rodriguez MA, Lee HJ, Wang M, Flowers C, Feng L, Esmaeli B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 10(9):1195-1203, 2024. e-Pub 2024. PMID: 38990564.
10. Gurumurthi A, Chin CK, Feng L, Fowler NH, Strati P, Hagemeister FB, Fayad LE, Westin JR, Obi C, Arafat J, Nair R, Steiner RE, Neelapu SS, Flowers CR, Nastoupil LJ. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial. EClinicalMedicine 74:102747, 2024. e-Pub 2024. PMID: 39161543.
11. Shah J, Devalaraju S, Baerman E, Lee IJ, Takigawa K, Machado AP, Catinis C, Shatila M, Varatharajalu K, Shafi M, Lee HC, Strati P, Thomas A, Wang Y. Gastrointestinal toxicities of proteasome inhibitor therapy. J Cancer Res Clin Oncol 150(7):334, 2024. e-Pub 2024. PMID: 38969842.
12. Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
13. Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
14. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. e-Pub 2024. PMID: 37985359.
15. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2024. PMID: 37822075.
16. Manzar GS, Cha EE, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Chihara D, Castillo LM, Nair R, Jain P, Neelapu SS, Rodriguez MA, Strati P, Nastoupil LJ, Gunther JR, Dabaja BS, Pinnix CC, Wu SY, Fang PQ. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Front Oncol 14:1447020, 2024. e-Pub 2024. PMID: 39324011.
17. Fiorcari S, Strati P, Dondi E. Editorial: Tumor microenvironment and hematological malignancies: new evidences and new questions. Front Immunol 15:1407981, 2024. e-Pub 2024. PMID: 38690284.
18. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
19. Li X, Henderson J, Gordon MJ, Sheikh I, Nastoupil LJ, Westin J, Flowers C, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41(11):1835-1837, 2023. e-Pub 2023. PMID: 37738975.
20. Mamlouk O, Strati P, Feng L, Sun R, Steiner RE, Nair R, Flowers CR, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with large B cell lymphoma with decreased kidney function. BJHaem, 2023. e-Pub 2023.
21. Li X, Henderson J, Nastoupil LJ, Westin JR, Flowers CR, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. A single cell atlas of CD19 chimeric antigen receptor T-cells from the infusion products of relapsed/refractory large B-cell lymphoma patients treated with axicabtagene ciloleucel. Cancer Cell, 2023. e-Pub 2023.
22. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
23. Strati P, Li X, Deng Q, Marques-Piubelli M, Henderson J, Balada G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra Cuentas E, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T-cell therapy is associated with bone marrow infiltration of clonally-expanded IFNγ-expressing CD8 T-cells. Cell Rep Med, 2023. e-Pub 2023.
24. Strati P, Pasvolsky O, Feng L, Xu G, Tewari SO, Varghese J, Ow K, Santiago M, Al Zaki A, Jallouk A, Neelapu SS, Kebriaei P, Shpall EJ, Ahmed S. ASCT vs CART for Patients with Relapsed LBCL in PR: Role of TMTV. Blood Adv 7(11):2586-2589, 2023. e-Pub 2023. PMID: 36745104.
25. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nehlsen R, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong D, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate Immune Cell Associated Neurotoxicity Syndrome in Patients with Large B-cell Lymphoma. Blood Advances, 2023. e-Pub 2023.
26. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma Patients in Complete Metabolic Response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
27. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
28. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
29. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
30. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Rohrbach R, Chang CC, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin JR, Arora R, Wang M, Locke F, Dreger P, Schmitt A, Müller-Tidow C, Poeck CH, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome predicts clinical responses to CD19-targeted CAR-T cell immunotherapy across international cohorts. Nature Medicine, 2023. e-Pub 2023.
31. Wu SY, Fang PQ, Wang EB, Ahmed S, Duvic M, Jain P, Castillo LEM, Nair R, Steiner RE, Strati P, Huen AO, Iyer SP, Pinnix CC, Dabaja BS, Gunther JR. Safety of concurrent radiation therapy with brentuximab vedotin in the treatment of lymphoma. Adv Radiat Oncol 8(6):101279, 2023. e-Pub 2023. PMID: 37448588.
32. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. e-Pub 2022. PMID: 36384092.
33. Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of Conditioning Chemotherapy on Lymphocyte Kinetics and Outcomes in LBCL Patients Treated with CAR T-cell Therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
34. Strati P, Coleman M, Champion R, Ma S, Patti C, Levy MY, Lossos IS, Geethakumari PR, Lam S, Calvo R, Higgins K, Budde LE. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol 199(1):76-85, 2022. e-Pub 2022. PMID: 35861370.
35. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
36. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
37. Romain G, Strati P, Rezvan A, Fathi M, Bandey IN, Adolacion JRT, Heeke D, Liadi I, Marques-Piubelli ML, Solis LM, Mahendra A, Vega F, Cooper LJ, Singh H, Mattie M, Bot A, Neelapu SS, Varadarajan N. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. J Clin Invest 132(17), 2022. e-Pub 2022. PMID: 35881486.
38. Yu L, Shi M, Cai QQ, Strati P, Hagemeister FB, Zhai QL, Li L, Fan X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, Iwaki N, Sato Y, Zhang L, Li J, Oksenhendler E, Xu-Monette ZY, Young KH. Clinical characteristics and outcomes of Castleman disease: A multicenter Consortium study of 428 patients with 15-year follow-up. American Journal of Cancer Research, 2022. e-Pub 2022.
39. Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2022. PMID: 34758610.
40. Shbib Dabaja B, Boyce-Fappiano D, Dong W, Damron E, Fang P, Gunther J, Rodriguez MA, Strati P, Steiner R, Nair R, Lee H, Abou Yehia Z, Shihadeh F, Pinnix C, Ng AK. Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experience. Clin Transl Radiat Oncol 35:64-69, 2022. e-Pub 2022. PMID: 35601797.
41. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
42. Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, Vega F, Agarwal NK. Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leuk Lymphoma 63(6):1-12, 2022. e-Pub 2022. PMID: 34969327.
43. Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, Lin Y, Iqbal M, Merryman RW, Strati P. A Multicenter Retrospective Study of Polatuzumab Vedotin in Patients with Large B-cell Lymphoma After CAR T-cell Therapy. Blood Adv 6(9):2757-2762, 2022. e-Pub 2022. PMID: 35240681.
44. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
45. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad LE, Fowler NH, Parmar S, Steiner RE, Hagemeister FB, Nair R, Lee HJ, Rodriguez MA, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin JR. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood. e-Pub 2022. PMID: 35512184.
46. Lötscher J, Martí I Líndez AA, Kirchhammer N, Cribioli E, Giordano Attianese GMP, Trefny MP, Lenz M, Rothschild SI, Strati P, Künzli M, Lotter C, Schenk SH, Dehio P, Löliger J, Litzler L, Schreiner D, Koch V, Page N, Lee D, Grählert J, Kuzmin D, Burgener AV, Merkler D, Pless M, Balmer ML, Reith W, Huwyler J, Irving M, King CG, Zippelius A, Hess C. Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. Cell 185(4):585-602.e29, 2022. e-Pub 2022. PMID: 35051368.
47. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
48. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):1-8, 2021. e-Pub 2021. PMID: 33942701.
49. Strati P, De Vos S, Ruan J, Maddocks KJ, Flowers CR, Rule S, Patel P, Xu Y, Wei H, Frigault MM, Calvo R, Dyer MJS. Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study. Haematologica 106(10):2774-2778, 2021. e-Pub 2021. PMID: 34233448.
50. Marques-Piubelli ML, Solis LM, Parra ER, Castillo LM, Gouni S, Nair R, Chihara D, Konopleva M, Wistuba II, Iyer SP, Vega F, Strati P. BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer J 11(9):153, 2021. e-Pub 2021. PMID: 34531377.
51. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma:1-10. e-Pub 2021. PMID: 34435552.
52. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
53. Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
54. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
55. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
56. Mamlouk O, Nair R, Iyer SP, Edwards A, Neelapu SS, Steiner RE, Adkins SA, Hawkins M, Saini N, Devashish K, Strati P, Mandayam S, Ahmed S. Safety and efficacy of CAR T-cell Therapy in Renal Transplant Recipients with B-cell Lymphoma. Blood 137(18):2558-2562, 2021. e-Pub 2021. PMID: 33512386.
57. Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, Wistuba II, Wierda WG, Konopleva M, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma 62(5):1-10, 2021. e-Pub 2021. PMID: 33327833.
58. Chacko JA, Strati P, Stout PW, Archer RL, Baltz BP, Chacko JG. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 49:102776, 2021. e-Pub 2021. PMID: 33508568.
59. Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 109(5):1414-1420, 2021. e-Pub 2021. PMID: 33309978.
60. Strati P, Cheng PTM, Steiner RE, Alcedo Andrade PE, Feng L, Sano D, Rao VA, Singh P, Miranda R, Gunther JR, Pinnix CC, Dabaja BS, Cuglievan B, Xing K, Villa D, Skinnider B, Sehn LH, Connors JM, Nieto Y, Ahmed S, Lee HJ, Savage KJ. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol 192(3):560-567, 2021. e-Pub 2021. PMID: 33517581.
61. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2021. PMID: 32932518.
62. Furqan F, Watson G, Samaniego F, Fayad LE, Kanagal-Shamanna R, Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma 61(12):2980-2984, 2020. e-Pub 2020. PMID: 32650677.
63. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
64. Jacob R, Strati P, Palaskas N, Lopez-Mattei JC, Marmagkiolis K, Buja M, Deswal A, Iliescu C. Lenalidomide-Induced Myocarditis, Rare but Possibly Fatal Toxicity of a Commonly Used Immunotherapy. JACC Case Rep 2(13), 2020. e-Pub 2020.
65. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner RE, Strati P, Ahmed SA, Iyer SP, Westin JR, Parmar S, Rodriguez MA, Nastoupil LJ, Neelapu SS, Flowers CR, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Favorable Risk Hodgkin Lymphoma treated with Contemporary Radiation Therapy. JAMA Netw Open 3(9):2013935, 2020. e-Pub 2020.
66. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall E, Neelapu SS, Tummala S, Linda Chi L. Clinical and Radiological Correlates of Neurotoxicity after Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Blood Adv 4(16):3943-3951, 2020. e-Pub 2020.
67. Yu L, Cai QQ, Strati P, Zhai QL, Li L, Wang X, Li J, Sun R, Zhang S, Miranda RN, Qian W. A Novel Predictive Model for Idiopathic Multicentric. The Oncologist 25(11):963-73, 2020. e-Pub 2020.
68. Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, Wei P, Khoury JD, You MJ, Loghavi S, Tang Z, Fang H, Thakral B, Medeiros LJ, Wang W. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mututations are associated with diffrent features. Blood Cancer J 8:86, 2020. e-Pub 2020.
69. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(7):1907-1913, 2020. e-Pub 2020. PMID: 31601688.
70. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad LE, Lee HJ, Nair R, Steiner R, Iyer SP, M Rodriguez A, Wang M, Flowers CR, Neelapu SS, Nastoupil LJ. Radiation Therapy Bridging Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-cell Lymphoma. Blood Adv 4(13):2871-2883, 2020. e-Pub 2020.
71. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New Paradigm for Radiation in Multiple Myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105(7):e355-e357, 2020. e-Pub 2020. PMID: 31919088.
72. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz S, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS. Clinical Efficacy of Anakinra to Mitigate CAR T-Cell Therapy-Associated Toxicity in Large B-cell Lymphoma. Blood Adv 4(13):3123-3127, 2020. e-Pub 2020.
73. Gunther JR, Pinnix CC, Glober G, Christopherson K, Fang P, Lee HJ, Ahmed S, Steiner RE, Nair R, Strati P, Neelapu SS, Nastoupil LJ, Dabaja BS. Partial Omission of Bleomycin for Early Stage Hodgkin Lymphoma Patients Treated with Combined Modality Therapy: Does Incomplete ABVD Lead to Inferior Outcomes?. EJHaem(1):272-276, 2020. e-Pub 2020.
74. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
75. Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, Chen H, Li Y, Manyam GC, Li Y, Montes-Moreno S, Piris MA, Young KH. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 10(5):49, 2020. e-Pub 2020. PMID: 32366834.
76. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
77. Greenbaum U, Ramdial JL, Olson A, Nieto Y, Strati P, Ahmed S, Neelapu SS, Tummala S, Chi L, Shpall EJ, Kebriaei P. Prolonged neurotoxicity in a lymphoma patient after CD19-directed CAR T-cell therapy: a case report and brief review of the literature. Adv Cell Gene Ther, 2020. e-Pub 2020.
78. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2020. PMID: 31073068.
79. Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma 61(1):1-5, 2020. e-Pub 2020. PMID: 31373240.
80. Lyapichev KA, Sukswai N, Strati P, Iyer SP, Medeiros LJ, Miranda RN. Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. Ann Diagn Pathol 43:151398, 2019. e-Pub 2019. PMID: 31630065.
81. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951-1959, 2019. e-Pub 2019. PMID: 31537528.
82. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
83. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
84. Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol 98(7):1611-1616, 2019. e-Pub 2019. PMID: 31093708.
85. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
86. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers (Basel) 11(7), 2019. e-Pub 2019. PMID: 31248056.
87. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood 133(26):2800-2802, 2019. e-Pub 2019. PMID: 31101626.
88. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. e-Pub 2019. PMID: 31076409.
89. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica 104(2):e65-e67, 2019. e-Pub 2019. PMID: 30190343.
90. Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A. Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(2):535-537, 2019. e-Pub 2019. PMID: 29911929.
91. Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma 60(2):507-510, 2019. e-Pub 2019. PMID: 29966471.
92. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
93. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
94. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103(9):e416-e418, 2018. e-Pub 2018. PMID: 29622656.
95. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1672-1676, 2018. e-Pub 2018. PMID: 29119847.
96. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
97. Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109-121, 2018. e-Pub 2018. PMID: 29143068.
98. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2018. PMID: 29196178.
99. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica 102(12):e494-e496, 2017. e-Pub 2017. PMID: 28798068.
100. Strati P, Benton CB, Manshouri T, Zhang Y, Bove JE, Sanchez-Petitto G, Verstovsek S. JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. Leuk Res 63:53-55, 2017. e-Pub 2017. PMID: 29101828.
101. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol 92(9):924-928, 2017. e-Pub 2017. PMID: 28556489.
102. Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, Cerhan JR, Slager SL, Shanafelt TD. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 178(3):394-402, 2017. e-Pub 2017. PMID: 28580636.
103. Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol 178(1):99-105, 2017. e-Pub 2017. PMID: 28386906.
104. Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
105. Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
106. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
107. Strati P, Chaffee KG, Achenbach SJ, Slager SL, Leung N, Call TG, Ding W, Parikh SA, Kay NE, Shanafelt TD. Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. Haematologica 102(1):e22-e25, 2017. e-Pub 2017. PMID: 27634202.
108. Kay NE, Strati P, LaPlant BR, Pettinger AM, Lesnick CE, Nikcevich D, Call TG, Ding W, Hanson CA, Shanafelt TD. A Randomized Phase II Trial Comparing Chemoimmunotherapy With or Without Bevacizumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia. Oncotarget 7(48):78269-78280, 2016. e-Pub 2016. PMID: 27861157.
109. Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol 3(9):e407-14, 2016. e-Pub 2016. PMID: 27570087.
110. Strati P, Gharaibeh KA, Leung N, Cosio FG, Call TG, Shanafelt TD. Solid organ transplant in individuals with monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. Br J Haematol 174(1):162-5, 2016. e-Pub 2016. PMID: 26436615.
111. Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, Chaffee KG, Call TG, Shanafelt TD. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica 101(4):458-65, 2016. e-Pub 2016. PMID: 26819053.
112. Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica 100(9):1180-8, 2015. e-Pub 2015. PMID: 26088927.
113. Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ. Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 15(7):420-7, 2015. e-Pub 2015. PMID: 25800543.
114. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(6):1878-80, 2015. e-Pub 2015. PMID: 25311497.
115. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
116. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer 121(6):876-82, 2015. e-Pub 2015. PMID: 25410759.
117. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res 38(10):1212-6, 2014. e-Pub 2014. PMID: 25217891.
118. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
119. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
120. Strati P, Ferrajoli A, Lerner S, O'Brien S, Wierda W, Keating MJ, Faderl S. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55(4):828-33, 2014. e-Pub 2014. PMID: 23808813.
121. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2014. e-Pub 2014. PMID: 24151050.
122. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
123. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11; quiz 2920, 2013. e-Pub 2013. PMID: 23896412.
124. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 13(2):S276-81, 2013. e-Pub 2013. PMID: 23969309.
125. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 2013. e-Pub 2013. PMID: 23801633.
126. Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek S. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma 54(7):1552, 2013. e-Pub 2013. PMID: 23121011.
127. Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk 13(3):287-91, 2013. e-Pub 2013. PMID: 23123105.
128. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2013. PMID: 23115106.

Invited Articles

1. Strati P, Gregory T, Majhail NS, Jain N. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review. JCO Oncol Pract 19(9):706-713, 2023. e-Pub 2023. PMID: 37406255.
2. Perrone S, Lopedote P, De Sanctis V, De Cumis II, Pulsoni A, Strati P. Combination of Novel Drugs with Modern Radiotherapy in the Treatment of Relapsed Lymphoma Patients. Cancers, 2023. e-Pub 2023.
3. Al Zaki A, McCurry D, Strati P. CAR T-cells and Macrophages in Large B-cell Lymphoma: Impact on Toxicity and Efficacy. Leuk Lymphoma 64(4):808-815, 2023. e-Pub 2023. PMID: 36891619.
4. Gouni S, Marques-Piubelli ML, Strati P. Follicular Lymphoma and Macrophages: Impact of Approved and Novel Therapies. Blood Adv 5(20):4303-4312, 2021. e-Pub 2021. PMID: 34570196.
5. Gudiol C, Lewis RE, Strati P, Kontoyiannis. Chimeric antigen receptor T-cell immunotherapy for the treatment of lymphoid malignancies: Is there an excess risk for infection?. Lancet Haematology 15:S2352-3026(20)30376-8, 2021. e-Pub 2021.
6. Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol 10:849, 2020. e-Pub 2020. PMID: 32670869.
7. Pollyea DA, Amaya M, Strati P, Konopleva M. Venetoclax for Acute Myeloid Leukemia: Changing the Treatment Paradigm. Blood Adv 3(24):4326-4335, 2019. e-Pub 2019.
8. Strati P, Ferrajoli A. Treating Older Patients with Chronic Lymphocytic Leukemia - A Personalized. Drugs Aging 36(9):841-851, 2019. e-Pub 2019.
9. Strati P, Neelapu SS. Chimeric Antigen Receptor-Engineered T-Cell Therapy in Lymphoma. Current Oncology Rep 21(5):38, 2019. e-Pub 2019.
10. Autore F, Strati P, Laurenti L, Ferrajoli A. Morphologic, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologic 103(6):931-938, 2018. e-Pub 2018.
11. Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book 38:592-603, 2018. e-Pub 2018. PMID: 30231316.
12. Strati P, Jain N, O’Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clinical Protocol 93(5):651-664, 2018. e-Pub 2018.
13. Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Evidence-Based Focused Review: Should Immunoglobulin Heavy Chain Variable Region Gene (IGHV) Mutation Status and Fluorescence in situ Hybridization (FISH) Testing Be Performed in All Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL)?. Blood 127(14):1752-60, 2016. e-Pub 2016.
14. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and Early Stage CLL: Diagnosis, Natural History, and Risk Stratification. Blood 126(4):454-62, 2015. e-Pub 2015.
15. Strati P, O’Brien S. Reply to Myelosuppression After Frontline Fludarabine, Cyclophosphamide and Rituximab in Chronic Lymphocytic Leukemia: Analysis of Persistent and New-Onset Cytopenia. Cancer 120(3):452, 2014. e-Pub 2014.
16. Strati P, Caligaris-Cappio F. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?. Curr Opin Oncol 23(5):455-60, 2011. e-Pub 2011. PMID: 21681094.
17. Camaschella C, Strati P. Recent advances in iron metabolism and related disorders. Internal and Emergency Medicine Journal 5:393-400, 2010. e-Pub 2010.

Other Articles

1. Braun A, Gouni S, Pulles A, Strati P, Minnema MC, Budde LE Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma. Am Soc Clin Oncol Educ Book 44(3):e433516, 2024. PMID: 38935881.
2. Perrone S, Lopedote P, De Sanctis V, Iamundo De Cumis I, Pulsoni A, Strati P Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond. Cancers (Basel) 15(10), 2023. PMID: 37345088.
3. Handley G, Khawaja F, Kondapi DS, Lee HJ, Kaufman GP, Neelapu SS, Fayad LE, Tummala S, Chi L, Strati P, Mulanovich VE Human Herpesvirus-6 Myelitis after Chimeric Antigen Receptor T-cell Therapy. Int J Infect Dis 112:327-329, 2021. PMID: 34600133.
4. Gudiol, C, Lewis, RE, Strati, P, Kontoyiannis, DP Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies. The Lancet Haematology 8(3):e216-e228, 2021. PMID: 33460558.
5. Fang H, Chuang HH, Strati P, Hu S, Shuai W, Medeiros LJ, Wang W Postchemotherapy Histiocyte-rich Pseudotumor Mimicking Residual Lymphoma: A Report of 11 Cases Correlating Clinicopathologic and Radiologic Findings. Am J Surg Pathol 45(2):160-168, 2021. PMID: 32769427.
6. Akcan T, Strati P, Yan M, Idowu M A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge. Case Rep Hematol 2018:9079462, 2018. PMID: 30647982.
7. Ho TP, Strati P, Chon TY 65-Year-Old Man With Weight Loss and Progressive Acral Necrosis. Mayo Clin Proc 92(4):605-608, 2017. PMID: 28238397.
8. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma 55(6):1425-7, 2014. PMID: 23987820.

Editorials

1. Strati P. CAR T-cell therapy: which product for which patient?. Blood 139(26):3673-3674, 2022. PMID: 35771558.
2. Strati, P, Neelapu, SS. CAR-T failure. Blood 137(19):2567-2568, 2021. PMID: 33983421.
3. Strati P, Neelapu SS. CAR-T failure: Beyond antigen loss and T cells. Blood 137(19):2567-2568, 2021.
4. Strati P, Green MG. A ticking clock for B-cell tumors. Nature Cancer 1(11):1035-1037, 2020.
5. Strati P. New Treatment Strategies for Patients with Relapsed Refractory Chronic Lymphocytic Leukemia: an Ongoing Challenge. Lancet Hematology 4(3):97-98, 2017.

Abstracts

1. Strati P, Jain S, Feldman T, Querfeld C, Kidder K, Bárcia R, Fogelson S, McCurley N, Kijlstra J. Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. American Society of Hematology, 2023. e-Pub 2023.
2. Strati P, Brandt A, Henderson J, Westin JR, Nastoupil LJ, Al Zaki A, Jallouk A, Adkins S, Shpall EJ, Kebriaei P, Ramdial J, Saini N, Ahmed S, Flowers CR, Neelapu SS. Germline Determinants of Toxicity and Efficacy in Patients with Large B-cell Lymphoma Treated with Anti-CD19 Autologous CAR T-cell Therapy. American Society of Hematology, 2023. e-Pub 2023.
3. Strati P, Feng L, Westin JR, Nair R, Fayad LE, Rodriguez MA, Chihara D, Malpica L, Henderson J, Gallardo M, Marques-Piubelli M, Turova P, Zaitsev A, Wang I, Flowers CR, Nastoupil LJ, Neelapu SS. Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study. American Society of Hematology, 2023. e-Pub 2023.
4. Al Zaki A, Feng L, Westin JR, Nair R, Fayad LE, Balada G, Adkins S, Shpall EJ, Kebriaei P, Marques-Piubelli M, Henderson J, Nastoupil LJ, Flowers CR, Ahmed S, Neelapu SS, Strati P. A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients with LBCL in PR at Day 30 After CAR T-cell Therapy. American Society of Hematology, 2023. e-Pub 2023.
5. Cha EE, Manzar GS, Corrigan KL, Yoder AK, Schrank BS, Nasr LF, Gunther JR, Strati P, Ahmed S, Fayad LE, Nair R, Steiner RE, Westin JR, Nastoupil LJ, Neelapu SS, Pinnix CC, Dabaja BS, Wu SY, Fang PQ. Outcomes and Toxicities in Patients with Diffuse Large B-cell Lymphoma of the Gastrointestinal Tract. ASTRO, 2023. e-Pub 2023.
6. Manzar GS, Wu, SY, Dudzinski SO, Rooney MK, Jallouk A, Yoder AK, Nasr LF, Gunther JR, Sallard G, Ahmed S, Fayad LE, Nair R, Steiner RE, Westin JR, Nastoupil LJ, Neelapu SS, Dabaja BS, Pinnix CC, Strati P, Fang PQ. Characterization of lymphopenia during bridging radiation therapy prior to CAR-T cell therapy in patients with aggressive B cell lymphomas. ASTRO, 2023. e-Pub 2023.
7. Manzar GS, Wu SY, Dudzinski SO, Jallouk A, Yoder AK, Nasr LF, Corrigan KL, Gunther JR, Ahmed S, Fayad LE, Nair R, Steiner RE, Westin JR, Neelapu SS, Dabaja BS, Strati P, Nastoupil LJ, Pinnix CC, Fang, PQ. Outcomes with bridging radiation therapy prior to CAR-T cell therapy in pts with aggressive B cell lymphomas. ASTRO, 2023. e-Pub 2023.
8. Strati P, Feng L, Westin JR, Nair R, Gouni S, Fayad LE, Rodriguez MA, Chihara D, Malpica L, Steiner RE, Gallardo M, Nastoupil LJ, Neelapu SS. A Phase II Investigator Initiated Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma. iCML, 2023. e-Pub 2023.
9. Samples LS, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Riedell PA, Dahiya S, Yared J, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik A, Hill BT, Kamdar MK, Shadman M. Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma. ASCO 2023, 2023. e-Pub 2023.
10. Strati P, Kim TM, Danilov A, Cheah CY, Yoon DH, Jurczak W, Sharma S, Yoon JL, Arduini S, Saeh J, Olsson RF, Gregory GP. Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). EHA, 2023. e-Pub 2023.
11. Pinnix CC, Dabaja BS, Gunther J, Fang P, Wu S, Ahmed SA, Steiner RE, Nair R, Strati P, Westin J, Fayad LE, Iyer SP, Rodriguez MA, Lee HJ, Samaniego F, Chihara D, Jain P, Feng L, Flowers CR, Neelapu SS, Nastoupil LJ. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-cell Lymphoma. ASH, 2022. e-Pub 2022.
12. Strati P, Christian B, Martin P, Champion R, Coleman M, Agajanian R, Smith SM, Venugopal P, Lossos IS, Kridel R, Calvo R, Higgins K, Stephens DM. Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial. ASH, 2022. e-Pub 2022.
13. Nieto Y, Valdez B, Thall P, Bassett R, Barnett M, Ramdial J, Srour S, Saini N, Hosing C, Alousi A, Qazilbash M, Popat U, Gulbis A, Shigle TL, Pacheco MG, Ledesma C, Strati P, Ahmed SA, Steiner RE, Westin JR, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Activity of the Combination of the PARP Inhibitor Olaparib with High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplant (ASCT) for Refractory Lymphomas. ASH, 2022. e-Pub 2022.
14. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed, SA, Parmar S, Nieto Y, Hosing C, Westin JR, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Jain P, Fayad LE, Wang M, Miranda RN, Vega F, Oki Y, Flowers CR, Neelapu SS, Swaminathan P Iyer SP. Updated results of an investigator-initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with survival analysis. ASH, 2022. e-Pub 2022.
15. Strati P, Kim TM, Danilov A, Cheah CY, Yoon DH, Jurczak W, Sharma S, Yoon JL, Arduini S, Saeh J, Olsson RF, Gregory GP. Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation. ASH, 2022. e-Pub 2022.
16. Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramdial J, Srour S, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil L, Mistry H, Shpall EJ, Nieto Y, Westin JR, Neelapu SS, Ahmed SA. Comorbidities Associated with Early Mortality After CD19 CAR-T Cell Therapy. ASH 2022, 2022. e-Pub 2022.
17. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin JR, Fayad LE, Chihara D, Malpica L, Iyer SP, Ahmed SA, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. ASH, 2022. e-Pub 2022.
18. Li X, Deng Q, Henderson J, Balada G, Deaton L, Cain T, Ahmed SA, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Fowler NH, Westin JR, Steiner RE, Nair R, Al-Atrash G, Neelapu SS, Strati P, Green MR. Targetable cellular etiology of prolonged cytopenia following CD19 CAR T-cell therapy. ASH, 2022. e-Pub 2022.
19. Strati P, Li X, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nehlsen R, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Flowers CR, Hong D, Westin JR, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. ASH, 2022. e-Pub 2022.
20. Mamlouk O, Strati P, Fang L, Steiner RE, Fayad LE, Nair R, Flowers CR, Saini N, Ramdial J, Srour S, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayalam S, Ahmed SA. Real World Analysis of Safety and Efficacy of CAR T-Cell Therapy in Lymphoma Patients with Reduced Kidney Function. ASCO, 2022. e-Pub 2022.
21. Steiner R, Strati P, Flowers C, Neelapu SS, Green MR, Nastoupil LR, Hagemeister FR, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin J. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma. ASCO, 2022. e-Pub 2022.
22. Strati P, Leslie LA, Shiraz P, Budde LE, Oluwole OO, Ulrickson M, Ramakrishnan A, Sun J, Shen R, Kanska J, McCroskery P, Dong J, Schupp MA, Xu H, Patel K. Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study. ASCO, 2022. e-Pub 2022.
23. Budde LE, Coleman M, Stevens D A, Ma S, Patti C, Levy M Y, Lossos I S, Ramakrishnan P, Geethakumari, SL, Calvo R, Higgins K, Strati P. Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial. ASCO, 2022. e-Pub 2022.
24. Strati P, Leslie L, Shiraz P, Budde E, Oluwole OO, Ulrickson M, Ramakrishnan A, Sun J, Shen R, Kanska J, McCroskery P, Dong J, Schupp M, Xu H, Patel K. Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): outcomes of the phase 2 ZUMA-14 study. EHA, 2022. e-Pub 2022.
25. Pinnix C, Dabaja B, Gunther J, Fang P, Wu S, Nastoupil LJ, Strati P, Nair R, Ahmed S, Steiner RE, Westin JR, Neelapu SS, Rodriguez MA, Lee HJ, Wang M, Fowler NH, Flowers CR, Feng L, Chi L, Esmaeli B. Response Adapted Ultra Low Dose Radiation Therapy for the Definitive Management of Orbital Indolent B-cell Lymphoma. ASTRO, 2022. e-Pub 2022.
26. Strati P, Hawkes E, Ghosh N, Tuscano J, Chu Q, Anderson MA, Patel A, Burgess MR, Hege K, Chhagan S, Boyanapalli S, Day T, Shen F, Mehta A. Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma. EHA, 2022. e-Pub 2022.
27. Strati P, Coleman M, Stevens D, Ma S, Patti C, Levy M, Lossos IS, Geethakumari PR, Lam S, Calvo R, Higgins K, Budde E. Acalabrutinib in Patients With Relapsed/Refractory (R/R) Marginal Zone. EHA, 2022. e-Pub 2022.
28. Strati P, Hawkes E, Ghosh N, Tuscano J, Chu Q, Anderson MA, Patel A, Burgess MR, Hege K, Chhagan S, Boyanapalli S, Day T, Shen F, Mehta A. Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). ASH, 2021. e-Pub 2021.
29. Damron E, Gunther J, Fang P, Wu S, Dabaja B, Neelapu SS, Nastoupil LJ, Ahmed SA, Strati P, Westin J, Fayad LE, Steiner RE, Nair R, Gombos D, Fowler NH, Pinnix CC. Primary Intraocular Lymphoma: Outcomes and Toxicity after Radiation Therapy. ARS, 2021. e-Pub 2021.
30. Bachanova V, Ghobadi A, Patel K, Flinn A, Shah P, Wong C, Wong L, Valamehr B, Atwal S, Chu YW, Elstrom RL, Strati P. Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma. ASH, 2021. e-Pub 2021.
31. Marques-Piubelli ML, Solis Soto L, Malpica Castillo L, Gouni S, Nair R, Chihara D, Iyer SP, Vega F, Strati P. Characterization of BCL-2 Alternative Proteins and Outcome in Patients with Peripheral T-cell Lymphoma (PTCL. ASCO, 2021. e-Pub 2021.
32. Gouni S, Westin JR, Feng L, Mistry M, Steiner RE, James J, Parmar S, Noorani M, Fowler NH, Horowitz S, Fayad LE, Iyer SP, Green MR, Hawkins M, Flowers CR, Ahmed SA, Nastoupil LJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. ASH, 2021. e-Pub 2021.
33. Patel K, Bachanova V, Goodman A, Pagel JM, Griffis K, Anderson M, Atwal S, Bickers C, Szabo P, Wong L, Chu YW, Elstrom RL, Strati P. Phase I Study of FT516, an Off-the-Shelf iPSC-derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma. ASH, 2021. e-Pub 2021.
34. Strati P, Chraniuk D, Gonzalez Barca E, Taszner M, Coleman M, Chien C, Nanda S, Rudinski M, Pillai RN, Jayaprakash V, Hahka-Kemppinen M, Kania M. Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma. ASH, 2021. e-Pub 2021.
35. Al Zaki A, Westin JR, Balada G, Feng L, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR After CAR T-cell Therapy. ASH, 2021. e-Pub 2021.
36. Chihara D, Nastoupil LJ, Strati P, Samaniego F, Feng L, Rodriguez MA, Fayad LE, Westin JR, Hagemeister FB, Wang M, Neelapu SS, Fowler NH. Long-term follow up of rituximab in combination with lenalidomide (R2) for patients with low tumor burden follicular lymphoma: update of phase 2 study at the MD Anderson Cancer Center. ASH, 2021. e-Pub 2021.
37. Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Balada G, Ayers A, Neelapu SS, Khurana A, Iqbal M, Lin Y, Merryman RW, Strati P. A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-cell Lymphoma Relapsed After Standard of Care CAR T-cell Therapy. ASH, 2021. e-Pub 2021.
38. Strati P, Bachanova V, Goodman A, Pagel JM, Castro JE, Griffis K, Anderson M, Atwal S, Elstrom R, Patel K. Preliminary results of a phase I trial of FT516, an off-the-shelf, high-affinity non-cleavable (hn)CD16-expressing induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in relapsed/refractory (R/R) B-cell lymphoma (BCL). ASCO, 2021. e-Pub 2021.
39. Marques-Piubelli ML, Parra Cuentas E, Feng L, Gallardo M, Solis Soto L, Wistuba II, Flowers CR, Neelapu SS, Vega F, Strati P. SIRPα and CSF1R Positive Tissue Macrophages are Increased in Patients with Follicular Lymphoma who Relapse after Frontline Lenalidomide and Rituximab. ASH, 2021. e-Pub 2021.
40. Cherng HJ, Sun S, Yang H, Deng Q, Fayad LE, Fowler NH, Parmar S, Ahmed SA, Steiner RE, Hagemeister FB, Nair R, Lee HJ, Rodriguez MA, Samaniego F, Iyer SP, Nastoupil LJ, Neelapu SS, Strati P, Westin JR, Green MR. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA to Predict Outcomes after CD19 CAR T-cell Therapy for Large B-cell Lymphoma. ASH, 2021. e-Pub 2021.
41. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin JR, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, EJl S, Neelapu SS, Kebriaei P, Ahmed A. The EASIX (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). ASH, 2020. e-Pub 2020.
42. Strati P, Watson G, Horowitz S, Nair R, Rodriguez MA, Steiner RE, Fayad LE, Westin JR, Neelapu. Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-cell. ASH, 2020. e-Pub 2020.
43. Srour S, Xu J, Al-Juhaishi T, Nair R, Steiner RE, Ahmed S, Strati P, Parmar S, Nastoupil L, Westin J, Lee HJ, Fowler N, Fayad LE, Dabaja B, Pinnix C, Fang P, Gunther J, Samaniego F, Wang M, Jain P, Nieto Y, Hosing C, Khouri I, Miranda R, Champlin R, Neelapu SS, Vega F, Flowers C, Iyer SP. Retrospective review of prognostic and predictors markers in newly diagnosed Angioimmunoblastic T cell lymphoma. ASH, 2020. e-Pub 2020.
44. Strati P, Furquan F, Westin J, Fayad LE, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Horowitz SB, Claussen CM, Mistry H, Neelapu SS. Prognostic Impact of Dose, Duration and Timing of Corticosteroid Therapy in Patients with Large B-cell Lymphoma Treated with Standard of Care Axicabtagene Ciloleucel (Axi-cel). ASCO, 2020. e-Pub 2020.
45. Harden A, Puebla-Osorio N, Najjar A, Strati P, Westin J, Nastoupil LJ, Mahadeo K, Neelapu SS, Schadler K. Modifiers of Endothelial Permeability in the Setting of CAR-t Therapy Related Immune Cell Associated Neurotoxicity Syndrome. ASCTC, 2020. e-Pub 2020.
46. Strati P, Puebla-Osorio N, Han G, Westin J, Nastoupil LJ, Ahmed S, Samaniego S, Fowler N, Fayad LE, Lee HJ, Flowers CR, Srour SA, Watson G, Wang L, Michael Green M, Neelapu SS. Cytokines Associated with Prolonged Cytopenia after Axicabtagene Ciloleucel in Patients with Relapsed or Refractory Large B-cell Lymphoma. IOYIF, 2020. e-Pub 2020.
47. Steiner RE, Cramer F, Singh P, Becnel M, Alcedo P, Chin C, Cuglievan B, Strati P, Ahmed S, Samaniego F, Gunther J, Pinnix CC, Fang P, Dabaja B, Feng L, Lee HJ. Brentuximab Vedotin with Chemotherapy for Advanced Stage Classical Hodgkin’s Lymphoma in a real world setting. ASCO, 2020. e-Pub 2020.
48. Strati P, Mistry H, Pulsifer B, Fayad LE, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Dabaja B, Noorani M, Claussen CM, Shpall EJ, Kebriaei P, Flowers CR, Westin J, Neelapu SS. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-cell Therapy. ASH, 2020. e-Pub 2020.
49. Nair R, Pinnix CC, Gunther J, Strati P, Westin J, Fayad LE, Hagemeister FB, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez RA, Samaniego F, Steiner RE, Dabaja B, Fang P, Wang M, Romaguera JE, Flowers CR, Noorani M, Feng L, Neelapu SS, Ahmed S, Lee HJ. M.D. Anderson experience of checkpoint inhibition in classical Hodgkin’s lymphoma. ASCO, 2020. e-Pub 2020.
50. Strati P, Puebla-Osorio N, Han G, Westin J, Nastoupil LJ, Ahmed S, Samaniego S, Fowler N, Fayad LE, Lee HJ, Flowers CR, Srour SA, Watson G, Wang L, Michael Green M, Neelapu SS. Cytokines Associated with Prolonged Cytopenia after Axicabtagene Ciloleucel in Patients with Relapsed or Refractory Large B-cell Lymphoma. AACR, 2020. e-Pub 2020.
51. Ahmed S, Furqan F, Strati P, Westin J, Fayad LE, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Horowitz SB, Hawkins M, Neelapu SS. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). ASCO, 2020. e-Pub 2020.
52. Strati P, Samaniego F, Gallardo M, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Kanagal Shamanna R, Vega F, Fowler NH, Flowers CR, Nastoupil LJ. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed After Frontline Lenalidomide and Rituximab. ASH, 2020. e-Pub 2020.
53. Strati P, Puebla-Osorio N, Han G, Westin J, Nastoupil LJ, Ahmed S, Samaniego S, Fowler N, Fayad LE, Lee HJ, Flowers CR, Srour SA, Watson G, Wang L, Michael Green M, Neelapu SS. Association between Cytokine Levels and Prolonged Cytopenia after Axicabtagene Ciloleucel (Axi-cel) in Patients with Refractory Large B-cell Lymphoma (LBCL). AACR, 2020. e-Pub 2020.
54. Mondello P, Strati P, Merryman R, Joffe E, Ruella M, Seshan VE, St Pierre F, Major A, Pophali P, Fiasconaro M, Ho C, Neal E, Lai CM, Spilberg G, Rajguru SA, Svoboda J, Witzig TE, Smith S, Armand P, Nastoupil LJ, Ansell SM, Zelenetz AD, Younes A, Salles G. R-CHOP versus R-Bendamustine with or without Rituximab maintenance in newly Diagnosed Follicular Lymphoma patients with high SUV at baseline PET. ASH, 2020. e-Pub 2020.
55. Damron EP, Boyce D, Gunther J, Pinnix CC, Fang P, Dong W, Rodriguez MA, Lee HJ, Ahmed S, Strati P, Flowers CR, Steiner RE, Nastoupil LJ, Nair R, Iyer S, Dabaja B. How Much Did We Impact The Risk Of Second Malignancies In Patients With Classical Hodgkin Lymphoma By Changing The Treatment Paradigm?. ASTRO, 2020. e-Pub 2020.
56. Furquan F, Schlette EJ, Vega F, Wistuba II, Solis Soto LM, Piubelli MLM, Wierda WG, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. AACR, 2020. e-Pub 2020.
57. Steiner RE, Becnel M, Cuglievan B, Nair R, Singh P, Strati P, Ahmed S, Samaniego F, Gunther J, Pinnix CC, Fang P, Dabaja B, Feng L, Lee HJ. Brentuximab Vedotin with Chemotherapy for Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant. ASH, 2020. e-Pub 2020.
58. Gouni S, Strati P, Gouni S, Westin JH, Nastoupil LJ, Steiner RE, Nair RJ, Fayad LE, Neelapu SS, Landgraf R, Bilbao D, Vega F, Agarwal NK. Use of Medium Potency Statins is associated with improved outcomes after frontline RCHOP in patients with Diffuse Large B -cell Lymphoma (DLBCL. ASH, 2020. e-Pub 2020.
59. Strati P, Adkins S, Nastoupil LJ, Westin JR, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic Recovery and Immune Reconstitution after Axi-cel CAR T-cell Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma. ASCO, 2019. e-Pub 2019.
60. Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic Value of Baseline SUVmax in Patients with Advanced Stage Follicular Lymphoma Receiving Frontline Rituximab-Based Therapy. ASCO, 2019. e-Pub 2019.
61. Gunther JR, Pinnix CC, Glober G, Lee HJ, Ahmed S, Steiner R, Nair R, Strati P, Neelapu SS, Nastoupil L, Dabaja BS. Partial Omission of Bleomycin for Patients with Early Stage Hodgkin Lymphoma Treated with Combined Modality Therapy: Does Incomplete ABVD Therapy Lead to Inferior Outcomes?. ASTRO, 2019. e-Pub 2019.
62. Strati P, DiNardo C, Daver N, Andreef M, Konopleva M. Targeting Apoptosis Pathways in Acute Myeloid Leukemia. SOHO, 2019. e-Pub 2019.
63. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Wistuba II, Burger JA. Characterization of Bone Marrow Tumor-Associated Macrophages in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. AACR, 2019. e-Pub 2019.
64. Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic Value of Pre-Treatment PET Scan in Patients with Follicular Lymphoma Receiving Frontline Therapy. iCML, 2019. e-Pub 2019.
65. Sano D, Strati P, Alcedo P, Rao VA, Singh P, Miranda RN, Gunther JR, Pinnix CC, Dabaja BS, Lei F, Lee HJ, Steiner RE. Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse. ASH, 2019. e-Pub 2019.
66. Pinnix CC, Gunther JR, Dabaja BS, Adkins S, Hawkins MC, Westin J, Fayad L, Ahmed S, Fowler NH, Hagemeister FB, Iyer SP, Rodriguez A, Lee HJ, Steiner RE, Nair R, Strati P, Parmar S, Samaniego F, Wang M, Neelapu SS, Nastoupil LJ. Radiation Therapy can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy For Relapsed/Refractory Large B-cell Lymphoma. ASH, 2019. e-Pub 2019.
67. Strati P, Alcedo Andrade PE, Sano D, Rao VA, Singh P, Miranda R, Gunther JR, Pinnix CC, Dabaja BS, Lee HJ, Steiner RE. Relapsed and Refractory Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): a US Analysis from MD Anderson Cancer Center. iCML, 2019. e-Pub 2019.
68. Strati P, Adkins S, Nastoupil LJ, Westin JR, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Clinical Implications of Cytopenias Beyond Day 30 after Axi-cel Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma. iCML, 2019. e-Pub 2019.
69. Strati P, Tummala S, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, George S, Neelapu SS, Linda Chi L. Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma. ASH, 2019. e-Pub 2019.
70. Dabaja B, Gule-Monroe M, Gunther JR, Milgrom S, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Nastoupil LJ, Neelapu SS, Pinnix CC, Fowler NH. Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Involvement: Can MRI Patter Help Predicting Outcome?. iCML, 2019. e-Pub 2019.
71. Fowler NH, Nastoupil LJ, Chin C, Strati P, Hagemeister FB, Fayad LE, Westin J, Forbes S, Khan J, Feng L, Nair R, Steiner RE, Samaniego F, Neelapu SS. A Phase I/II study of Lenalidomide plus Obinutuzumab, in relapsed Indolent Lymphoma. ASH, 2019. e-Pub 2019.
72. Strati P, Johnson RJ, Forbes S, Nastoupil LJ, Samaniego F, Davis RE, Green M, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Fowler NH. Predictive Factors of Response and Survival of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. ASH, 2019. e-Pub 2019.
73. Fowler N, Jurczak W, Cordoba-Mascuñano R, Abrisqueta Costa P, Strati P, Yang W, Kania M, Kauh J, and Ferreri A. A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma. ESMO, 2019. e-Pub 2019.
74. Strati P, Phansalkar K, Ahmed MA, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin J, Noorani M, Nastoupil LJ, Davis RE, Fowler NH, Neelapu SS. BR vs RCHOP as Initial Treatment for Advanced Stage Follicular Lymphoma: A Matched-Pair Analysis. EHA, 2019. e-Pub 2019.
75. Strati P, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Burger JA. Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. ASH, 2018. e-Pub 2018.
76. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Montillo M, Gentile M, Morabito F, Molica S, Falcucci P, D’Arena G, Murru R, Vincelli D, Efremov DG, Visentin A, Reda G, Tisi MC, Vitale C, Rigolin GM, Ferrajoli A, Laurenti L. LDH as a Predictive Marker in Patients with CLL and Trisomy 12. SOHO, 2018. e-Pub 2018.
77. Strati P, Takahashi K, Wang F, Tambaro FP, Keating MJ, Ferrajoli A, Estrov Z, Thompson PA, Jain P, Bose P, Futreal A, Wierda W. The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype. SOHO, 2018. e-Pub 2018.
78. Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler N, Hagemeister F, Kwak L, Lee H, Wang M, Westin J, Ruben CE, Wesson ET, Fanale MA. The Combination of Romidepsin and Alisertib is a Safe and Effective Regimen for Relapsed/Refractory Hodgkin and T-cell Lymphomas: a Phase I Study. EHA, 2018. e-Pub 2018.
79. Strati P, Takahashi K, Keating MJ, Thompson PA, Hinojosa C, Rodriguez DR, Daver NG, Jain N, Burger JA, Estrov Z, O’Brien S, Wierda W, Kantarjian H, Futreal A, Ferrajoli A. Combination of Lenalidomide and Rituximab in Patients with Treatment-Naive and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response. ASH, 2018. e-Pub 2018.
80. Strati P, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Burger JA. Achievement of Complete Remission (CR) is a Desirable Endpoint for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib. ASCO, 2018. e-Pub 2018.
81. Strati P, Garcia-Manero G, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo C, Short N, Yilmaz M, Naqvi K, Pierce SA, Cortes J, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. EHA, 2018. e-Pub 2018.
82. Thompson PA, Srivastava J, Strati P, Jorgensen J, Hether T, Keating MJ, O’Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Undetectable-Minimal Residual Disease (U-MRD6) (10-6 sensitivity) is Associated with Best Progression-free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10-4 sensitivity) with First-line FCR. ASH, 2018. e-Pub 2018.
83. Strati P, Takahashi K, Wang F, Tambaro FP, Keating MJ, Ferrajoli A, Estrov Z, Thompson PA, Jain P, Bose P, Futreal A, Wierda W. The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype. TxSCO, 2018. e-Pub 2018.
84. Strati P, Garcia-Manero G, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo C, Short N, Yilmaz M, Naqvi K, Pierce SA, Cortes J, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. ASCO, 2018. e-Pub 2018.
85. Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib Therapy Improves Renal Function in Patients with Primary Myelofibrosis. ASH, 2018. e-Pub 2018.
86. Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler N, Hagemeister F, Kwak L, Lee H, Wang M, Westin J, Ruben CE, Wesson ET, Fanale MA. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas. ASH, 2017. e-Pub 2017.
87. Ferrajoli A, Strati P, Burger JA, O’Brien SM, Wierda WG, Estrov Z, Zacharian G, Keating MJ. Consolidation Treatment with Lenalidomide Following Frontline or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia. iwCLL, 2017. e-Pub 2017.
88. Strati P, Burger JA, O’Brien SM, Wierda WG, Estrov Z, Zacharian G, Keating MJ, Ferrajoli A. Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia. SOHO, 2017. e-Pub 2017.
89. Strati P, Burger JA, O’Brien SM, Wierda WG, Estrov Z, Zacharian G, Keating MJ, Ferrajoli A. Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia. IACRLRD Symposium, 2017. e-Pub 2017.
90. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O’Brien SM, Rezvani K, Kantarjian H, Burger JA, Hinojosa C, Keating MJ, Estrov Z. Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia. ASH, 2017. e-Pub 2017.
91. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D’Arena G, Murru R, Vincelli D, Padova D, Reda G, Vitale C, Ferrajoli A, Laurenti L. LDH as predictive parameter in treatment-naïve patients with +12 chronic lymphocytic leukemia. EHA, 2017. e-Pub 2017.
92. Hu B, Wang F, Yuanqing Y, Kim E, Patel K, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Do KA, Keating M, Burger J, Ferrajoli A, Wierda W, Futreal A, Takahashi K. Landscape of somatic mutations and their impact on response and outcomes from lenalidomide-based therapies in patient with chronic lymphocytic leukemia. EHA, 2017. e-Pub 2017.
93. Strati P, Keating MJ, Wierda WG, Estrov Z, Jain N, Burger JA, Hinoiosa C, Ferrajoli A. Durable Responses are Observed in Patients with Chronic Lymphocytic Leukemia (CLL) after Discontinuation of Lenalidomide Treatment. iwCLL, 2017. e-Pub 2017.
94. Strati P, Thompson PA, Keating MJ, Hinojosa C, Rodriguez DL, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien S, Wierda WG, Ferrajoli A. A Phase II Study of the Combination of Lenalidomide and Rituximab as Frontline Treatment in Patients with Chronic Lymphocytic Leukemia. iwCLL, 2017. e-Pub 2017.
95. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D’Arena G, Murru R, Vincelli D, Padova D, Reda G, Vitale C, Ferrajoli A, Laurenti L. Prognostic Study of clinic-biological characteristics in treatment-naïve patients affected by CLL with +12. iwCLL, 2017. e-Pub 2017.
96. Strati P, Shanafelt TD, LaPlant BR, Pettinger AM, Lesnick CE, Nikcevich D, Call TG, Ding W, Hanson CA, Kay NE. Low Baseline CCL-3 and CCL-4 Levels Predict Response to Bevacizumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). ASH LB, 2016. e-Pub 2016.
97. Strati P, Shanafelt TD, LaPlant BR, Pettinger AM, Lesnick CE, Nikcevich D, Call TG, Ding W, Hanson CA, Kay NE. The Addition of Bevacizumab to Chemoimmunotherapy Prolongs Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) Through Modulation of the Microenvironment. AACR, 2016. e-Pub 2016.
98. Thompson PA, Strati P, Keating MJ, O’Brien SM, Ferrajoli A, Burger JA, Faderl S, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo C, Daver NG, Jabbour E, Wierda WG. Early achievement of MRD-negativity in IGHV-mutated (IGHV-M) patients portends highly favorable outcomes after first-line treatment of CLL with fludarabine, cyclophosphamide and rituximab (FCR). Serial monitoring for minimal residual disease (MRD) in blood after achieving MRD-negativity predicts subsequent clinical relapse. ASH, 2016. e-Pub 2016.
99. Strati P, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Kay NE, Ding W, Parikh SA, Jelinek DF, Hanson CA, Shanafelt TD. CD49d expression is associated with development of lymphadenopathy in patients with Monoclonal B-cell lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL). EHA, 2016. e-Pub 2016.
100. Strati P, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Kay NE, Ding W, Parikh SA, Jelinek DF, Hanson CA, Shanafelt TD. CD49d expression is associated with development of lymphadenopathy in patients with Monoclonal B-cell lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL). ASH LB, 2016. e-Pub 2016.
101. Strati P, Bose P, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Bueso-Ramos CE, Verstovsek S. Immature Platelet Fraction is Associated with JAK2 V617F Mutation and Features of Advanced Disease in Myelofibrosis. ASH, 2016. e-Pub 2016.
102. Alhuraiji A, Falchi L, Keating MJ, Estrov Z, Strati P, Wierda WG, Jain N, Thompson PA, Ferrajoli A. Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes. ASH, 2016. e-Pub 2016.
103. Strati P, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Kay NE, Ding W, Parikh SA, Jelinek DF, Hanson CA, Shanafelt TD. CD49d expression associates with small lymphocytic lymphoma (SLL) presentation of chronic lymphocytic leukemia (CLL). ASCO, 2016. e-Pub 2016.
104. Strati P, Thompson PA, Keating MJ, Hinojosa C, Rodriguez DR, Wang X, Daver NG, Jain N, Burger JA, Estrov Z, O’Brien S, Wierda W, Kantarjian H, Ferrajoli A. A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-naïve and Relapsed Chronic Lymphocytic Leukemia. ASH, 2016. e-Pub 2016.
105. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D’Arena G, Murru R, Vincelli D, Padova D, Reda G, Vitale C, Ferrajoli A, Laurenti L. LDH Levels Predict Progression-Free Survival in Treatment-Naive Patients with Trisomy 12 Chronic Lymphocytic Leukemia. ASH, 2016. e-Pub 2016.
106. Strati P, Chaffee KG, Achenbach SJ, Slager SL, Schwager SM, Call TG, Leung N, Shanafelt TD. Prognostic Impact of Renal Insufficiency (RI) at Diagnosis in Patients with Chronic Lymphocytic Leukemia (CLL). ASCO, 2015. e-Pub 2015.
107. Strati P, Chaffee KG, AchenbachSJ, Schwager SM, Call TG, Kay NE, Cerhan JR, Slager SL, Shanafelt TD. Disease Progression and Complications are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. iwCLL, 2015. e-Pub 2015.
108. Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD. Renal Complications of Chronic Lymphocytic Leukemia/Monoclonal B-cell Lymphocytosis (CLL/MBL). National ACP, 2015. e-Pub 2015.
109. Strati P, Gharaibeh KA, Leung N, Cosio F, Call TG, Shanafelt TD. Kidney Transplant (KT) in Individuals with Monoclonal B-cell lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL). IKMG, 2015. e-Pub 2015.
110. Strati P, Chon TY. Atypical presentation of a Common Disease of the Elderly. MN ACP, 2015. e-Pub 2015.
111. Strati P, Uhm JH, Hanson CA, Chaffee KG, Achenbach SJ, Call TG, Shanafelt TD. Diagnostic Role of Lumbar Puncture (LP) for the diagnosis of Central Nervous System (CNS) Involvement by Chronic Lymphocytic Leukemia(CLL)/Richter Syndrome (RS). SOHO, 2015. e-Pub 2015.
112. Strati P, Chaffee KG, Achenbach SG, Call TG, Kay NE, Cerhan J, Slager S, Shanafelt TD. Comorbidity and cause of death in patients with chronic lymphocytic leukemia (CLL). AACR, 2015. e-Pub 2015.
113. Strati P, Uhm JH, Hanson CA, Chaffee KG, Achenbach SJ, Call TG, Shanafelt TD. Central Nervous System Involvement By Chronic Lymphocytic Leukemia. ASH, 2015. e-Pub 2015.
114. Strati P, Uhm JH, Hanson CA, Chaffee KG, Achenbach SJ, Call TG, Shanafelt TD. Prevalence and Characteristics of Central Nervous System (CNS) disease involvement by Chronic Lymphocytic Leukemia (CLL). EHA, 2015. e-Pub 2015.
115. Abi Aad S, Daver N, Strati P, Cortes J, Garcia-Manero G, Mathisen M, Ravandi F, Kadia T, O'Brien S, Bivins C, Pierce S, Kantarjian H, Jabbour E. High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse. ASCO, 2014. e-Pub 2014.
116. Ciccone M, Vitale C, Hinojosa C, Keating MJ, Pemmaraju N, O'Brien S, Burger JA, Thomas DA, Kantarjian H, Strati P, Wierda WG, Ferrajoli A. Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL). ASH, 2014. e-Pub 2014.
117. Strati P, Patel P, Tosh J. A Case of Vancomycin-Induced Thrombocytopenia. MN ACP, 2014. e-Pub 2014.
118. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Bone Marrow (BM) May be More Informative than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL),. ASH, 2013. e-Pub 2013.
119. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). EHA, 2013. e-Pub 2013.
120. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Achieving Bone Marrow CLL MRD disease-free status with 1st-line FCR is associated with improved PFS and can be considered a primary treatment objective. EHA, 2013. e-Pub 2013.
121. Strati P, Overman MJ, Fowler N, Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad LE. Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). ASH, 2013. e-Pub 2013.
122. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Bone Marrow (BM) May be More Informative than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL). SOHO, 2013. e-Pub 2013.
123. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. ASH, 2013. e-Pub 2013.
124. Jabbour E, Kantarjian H, Strati P, Cortes J, O’Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Dinardo C, Daver N, Kadia T, Wierda WG, Wei Y, Colla S, Borthakur G, Estrov Z, Garcia-Manero G. Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). ASH, 2013. e-Pub 2013.
125. Strati P, Keating MJ, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for CLL patients with del17p. ASCO, 2013. e-Pub 2013.
126. Strati P, Wierda W, Burger J, Ferrajoli A, Tam CS, Lerner S, Keating MJ, O’Brien S. Prolonged cytopenia related to FCR in CLL. EHA, 2013. e-Pub 2013.
127. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia. ASH, 2013. e-Pub 2013.
128. Strati P, Keating MJ, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for CLL patients with del17p. EHA, 2013. e-Pub 2013.
129. Strati P, Keating MJ, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for CLL patients with del17p. iwCLL, 2013. e-Pub 2013.
130. Strati P, Overman MJ, Fowler N, Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad LE. Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). SOHO, 2013. e-Pub 2013.
131. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Achieving Bone Marrow CLL MRD disease-free status with 1st-line FCR is associated with improved PFS and can be considered a primary treatment objective. iwCLL, 2013. e-Pub 2013.
132. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. SOHO, 2012. e-Pub 2012.
133. Strati P, Kantarjian H, Thomas D, O’Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi R, Cortes JE. HyperCVAD Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia. ASH, 2012. e-Pub 2012.
134. Strati P, Kantarjian H, Thomas D, O’Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi R, Cortes JE. HyperCVAD Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia. SOHO, 2012. e-Pub 2012.
135. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. ASH, 2012. e-Pub 2012.
136. Strati P, Abruzzo LV, Wierda WG, O’Brien S, Ferrajoli A, Keating MJ. Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12. ASH, 2012. e-Pub 2012.
137. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). ASH, 2012. e-Pub 2012.
138. Lazzari C, Gregorc V, Filipski K, Strati P, Sparreboom A. Association of ABCC2 polymorphism with cisplatin disposition and efficacy. ESMO, 2010. e-Pub 2010.
139. Rossoni G, Strati P, Caligaris-Cappio F. Aggressive Mastocytosis and Guillain-Barre’ Syndrome. SIMI, 2007. e-Pub 2007.
140. Rossoni G, Strati P, Caligaris-Cappio F. Squamocellular Lung Cancer Stage IIIA Treated with Radiation Therapy Only. SIMI, 2007. e-Pub 2007.

Book Chapters

1. Furqan, F, Strati, P. Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy, 537-547, 2023.
2. Greenbaum, U, Ramdial, JL, Afrough, A, Alsfeld, LC, Ghanem, S, Daher, M, Olson, AL, Kebriaei, P, Strati, P, Steiner, RE, Ahmed, S, Tanner, MR, Neelapu, SS, Rezvani, K, Shpall, E. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, 509-524, 2023.
3. Strati P, Konopleva M, Wierda W. Cell Death. In: Hoffman Manual of Hematology: Basic Principles and, 2022.
4. Strati P, Gunther JR, Medeiros LJ, Nastoupil LJ. Follicular Lymphoma. In: The MD Anderson Manual of Medical Oncology, Fourth Edition, 2022.
5. Furquan F, Strati P. Miscellaneous Complications of CAR T Cell Therapy. In: Manual of Stem Cell Transplantation and Cellular Therapies for Hematological Malignancies, 2022.
6. Greenbaum U, Ramdial JL, Afrough A, Alsfeld LC, Ghanem S, Daher M, Olson A, Kebriaei P, Strati P, Steiner RE, Ahmed SA, Tanner MR, Neelapu SS, Rezvani K, Shpall EJ. Cellular Therapy Associated Cytokine Release Syndrome. In: Manual of Stem Cell Transplantation and Cellular Therapies for Hematological Malignancies, 1e, 2022.
7. Puebla-Osorio N, Strati P, Neelapu S. The Microenvironment in Follicular Lymphoma. In: Follicular Lymphoma, Springer Nature, 2019.
8. Strati P, Fountain E, Fowler N. Immunotherapy for Follicular Lymphoma. In: Follicular Lymphoma, Springer Nature, 2019.
9. Chaekal O, Strati P, Van Besien K. Cellular Therapy for Follicular Lymphoma. In: Follicular Lymphoma, Springer Nature, 2019.
10. Strati P, Patel S, Nastoupil L, Michelle FA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy. In: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book, 2018.
11. Caligaris-Cappio F, Camaschella C, Strati P. Emergencies in Hematology. In: Medicina D’Urgenza Pratica e Progresso, 2nd Edition. CGEMS, 2013.